Detalhe da pesquisa
1.
Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
Diabetes Obes Metab
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751362
2.
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
Clin Cancer Res
; 30(3): 489-497, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37982848
3.
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor.
J Med Chem
; 65(12): 8208-8226, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35647711
4.
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
Nat Med
; 27(6): 1079-1087, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34127852
5.
De novo lipogenesis is essential for platelet production in humans.
Nat Metab
; 2(10): 1163-1178, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929234
6.
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.
Sci Transl Med
; 11(492)2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092695